Study: Alternatives for aspirin can protect heart patients from dangerous lumps

A new study has concluded that it may be better for heart patients in the recovery phase to the limited surgical interventions to continue to take a specific type of blood flow medicine to prevent heart attacks or strokes, instead of continuing aspirin. Patients usually receive a double anticoagulant treatment using both aspirin and one of the B2 WI -12 receptors (P2Y12), which are protein receptors that occur on the surface of the platelets and play an important role in blood clot, in the early stages to the coronary arteries, which are a procedure aimed at the treatment of arterial blocks or to prevent this. After a few months, patients usually turn from double treatment after using aspirin daily life. However, the evidence that supports the use of aspirin is due to studies conducted more than four decades ago, which raised questions about their suitability for modern medical practices, especially in light of the major developments in medicine and treatment techniques. P2Y12 receptors include medicines such as Clopidogrel and Ticagrelor can be more effective than low -dose -aspirin to prevent heart attacks and stroke. They participated in 5 previous clinical trials that concluded that continuing to take future inhibitors (P2Y12) and stopped eating aspirin, linked to low death figures, heart attacks and strokes that matched the ongoing aspirin, without increasing the risk, the risk of severe bleeding. With new data from long -term clinical experiences, it is possible to more accurately determine the effectiveness of this medication. Generally, experiments included 16,117 patients who received either a future brake (P2Y12) or aspirin after the double treatment was completed after the catheter was performed. After an average follow -up period that spans about four years, therapy was associated with future inhibitors (P2Y12) to a decrease in the risk of death with heart disease, heart attacks or stripes 23% compared to aspirin without a difference mentioned in the levels of severe bleeding. This means saving one patient from the risk of death due to cardiovascular disease, a heart attack or a stroke of every 46 patients taking future brakeers (P2Y12), against those who take aspirin to double treatment. In an article published with the study, it is said that the results generally indicate that future inhibitors (P2Y12) should be elected over aspirin “due to the low negative negative effects on the heart and brain vessels without increasing the risk of severe bleeding in the medium term.” However, the article indicated that since the advice for patients continues to lifelong catheter, there is a need for large experiments that are compared directly between the two different strategies with the follow -up for a longer period.